Interventional and diagnostic radiologists are leading the way in this surge, accounting for about 45% of IV RPT administrations, according to Medicare Part B claims. 

The dispute centered around the pharmaceutical company's request for the shot to be approved for those aged 65 and over, a demographic the FDA argued was not properly represented in a 40,000-person clinical study. The company has agreed to perform additional research after the shot goes to market, having appeased regulators with safety data.

A U.S. District Court in Texas ruled that the agency overstepped its regulatory authority in passing the 2024 Biden-era reporting requirement, which would require stakeholders to spend more than 100 hours filling out a long form to give the agency more oversight of transactions. 

EMS colleagues with many years on the job but not much direct trauma exposure set the stage for suboptimal patient outcomes.

A pilot project involving portable imaging in patients’ homes following injuries has been a game changer for one community.

Researchers explored data from more than 123,000 patients, noting that dozens of the adverse complications included on current labels can safely be removed. 

As soon as Esperion Therapeutics gained FDA clearance for Nexletol in 2020, competitors started trying to copy it. The company is fighting back. 

Funds will be directed toward the development of new point-of-care tools that reduce the reliance on operator experience, improve reproducibility and increase diagnostic speed.